UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1

PloS one, 2016-12, Vol.11 (12), p.e0168904-e0168904

2016

Volltextzugriff (PDF)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Frontiers in oncology, 2021-07, Vol.11, p.684867-684867

2021

Volltextzugriff (PDF)

Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling

International journal of oncology, 2016-05, Vol.48 (5), p.2079-2086

2016

Volltextzugriff (PDF)

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China

BMC cancer, 2024-01, Vol.24 (1), p.22-22, Article 22

2024

Volltextzugriff (PDF)

The mechanism of all- trans retinoic acid in the regulation of apelin expression in vascular endothelial cells

Bioscience reports, 2017-12, Vol.37 (6)

2017

Volltextzugriff (PDF)

Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling

Oncology letters, 2016-09, Vol.12 (3), p.2189-2193

2016

Volltextzugriff (PDF)

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of hematology and oncology, 2023-05, Vol.16 (1), p.50-50, Article 50

2023

Volltextzugriff (PDF)

Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis

Biomedical engineering online, 2021-11, Vol.20 (1), p.1-117, Article 117

2021

Volltextzugriff (PDF)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920905424-1758835920905424

2020

Volltextzugriff (PDF)

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

Cancer medicine (Malden, MA), 2024-02, Vol.13 (3), p.e6855-n/a

2024

Volltextzugriff (PDF)

Efficacy and safety of apatinib plus docetaxel for non-squamous non-small cell lung cancer with bone metastases

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21741-e21741

2020

Volltextzugriff (PDF)

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241264730

2024

Volltextzugriff (PDF)

Inducible T-cell co-stimulators regulate the proliferation and invasion of human hepatocellular carcinoma HepG2 cells

Biological research, 2018-01, Vol.51 (1), p.2-2, Article 2

2018

Volltextzugriff (PDF)

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

Tumor biology, 2014-11, Vol.35 (11), p.11381-11389

2014

Volltextzugriff (PDF)

Down-regulation of miRNA-30c predicts poor prognosis in Colorectal Cancer patients

Revista română de medicină de laborator, 2016-12, Vol.24 (4), p.369-375

2016

Volltextzugriff (PDF)

Status of non-classical mononuclear platinum anticancer drug development

Mini reviews in medicinal chemistry, 2009-10, Vol.9 (11), p.1357

2009

Volltextzugriff (PDF)

Circular RNA: biogenesis, degradation, functions and potential roles in mediating resistance to anticarcinogens

Epigenomics, 2020-02, Vol.12 (3), p.267-283

2020

Volltextzugriff (PDF)

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

The lancet respiratory medicine, 2022-11, Vol.10 (11), p.1019-1028

2022

Volltextzugriff (PDF)

Music intervention on physiological and psychological responses of patients with cancer: A protocol for meta-analysis

Medicine (Baltimore), 2021-02, Vol.100 (8), p.e24865-e24865

2021

Volltextzugriff (PDF)

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

Cell death & disease, 2020-10, Vol.11 (10), p.851, Article 851

2020

Volltextzugriff (PDF)

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.9482-9483

2022

Volltextzugriff (PDF)

First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

Blood, 2022-11, Vol.140 (Supplement 1), p.9473-9474

2022

Volltextzugriff (PDF)

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Journal of thoracic oncology, 2022-11, Vol.17 (11), p.1297-1305

2022

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(114)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China

The mechanism of all- trans retinoic acid in the regulation of apelin expression in vascular endothelial cells

Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

Efficacy and safety of apatinib plus docetaxel for non-squamous non-small cell lung cancer with bone metastases

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

Inducible T-cell co-stimulators regulate the proliferation and invasion of human hepatocellular carcinoma HepG2 cells

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

Down-regulation of miRNA-30c predicts poor prognosis in Colorectal Cancer patients

Status of non-classical mononuclear platinum anticancer drug development

Circular RNA: biogenesis, degradation, functions and potential roles in mediating resistance to anticarcinogens

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Music intervention on physiological and psychological responses of patients with cancer: A protocol for meta-analysis

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Aktive Filter

Suchergebnisse filtern